Viva Biotech Holdings
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Cheney Chen
- Full Time Employees
- 2,169
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- No.735, Ziping Road Shanghai SH China 201318
- IPO Date
- May 9, 2019
- Website
- vivabiotech.com
- Similar Companies
- Business
- Viva Biotech Holdings (1873.HK) is a China-based investment holding company principally engaged in providing structure-based drug discovery (SBDD) and contract development and manufacturing organization (CDMO) services to global biotechnology and pharmaceutical customers for preclinical and innovative drug development programs. Founded in 2008 and headquartered in Shanghai, China, the company offers comprehensive one-stop solutions including protein expression, purification and structural biology using X-ray crystallization and Cryo-EM; hit discovery via DEL, ASMS screening, fragment-based drug discovery (FBDD) and affinity selection; bioassays, biomolecular interactions, ADME/PK studies; therapeutic antibody discovery, expression and production; computer-aided drug design (CADD/AIDD), medicinal chemistry from hit-to-lead optimization, custom synthesis, chemical analysis, purification and kilogram-scale up; PROTAC/molecular glue and XDC platforms; as well as small molecule active pharmaceutical ingredients (API) development, formulation, GMP-compliant manufacturing through subsidiary Langhua Pharma, and CMC filing support; alongside an equity-for-service (EFS) model investing in high-potential biotech startups. It operates primarily in the United States, China, Europe and other regions, serving biopharma innovators across small molecules and biologics modalities with laboratories in Shanghai, Jiaxing, Suzhou and Chengdu. Recent developments include CRO revenue returning to positive growth in the 2025 interim period driven by AI-enabled initiatives contributing nearly 10% of revenue and strategic alliances with domestic pharmaceutical firms; enhanced CDMO profitability with preparations for new commercial projects and PPQ production underway following full acquisition of Zhejiang Langhua Pharmaceutical; portfolio companies raising approximately US$293.6 million with 228 pipeline projects and 18 investment exits; new investments in assets like Kriya, Piara, Bioabs, Dogma, Arrosia, Basking, Cybrexa and FuseBio; establishment of an RMB 250 million biopharmaceutical investment fund via subsidiary Hangzhou Viva Zongchen in May 2025; and restructuring of Viva Biotech Shanghai into a joint stock limited company in September 2024.
Company News
Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up
Viva Biotech Accelerates AI-Driven Drug Discovery and Advance the 'Lab-in-the-Loop' with NVIDIA
Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities
Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry
Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights
Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth
Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection
Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D
Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in Global Expansion
Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms
Vita Biotech Retains CBIH Services for Clinical Studies
Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future
Viva Biotech Secures Approximately US$ 210 Million Funding
Viva Biotech (1873.HK) Announces 2023 Interim Results: Solid Growth in Main Business, Significant Rebound in Profitability
Viva Biotech's Portfolio Company Riparian Pharmaceuticals Announces Exclusive License Agreement and Research Agreement with Pfizer for Novel Cardiovascular Programs
Viva Biotech's Portfolio Company DTx Pharma Reached the Acquisition Agreement with Novartis
Viva Biotech Revenues Surge on Move Into Contract Drug Manufacturing
Totient, a Viva Biotech Portfolio Company, has been Acquired by AbSci
Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse